Industry Focus
Healthcare: Never Will I Ever Buy Pre-Clinical Biotech Stocks. No Way!
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:20:03
- Mas informaciones
Informações:
Sinopsis
Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.
